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Abstract
Background: Presently, tuberculosis (TB) poses a global threat to human health. The development of reliable
laboratory tools is vital to the diagnosis and treatment of TB. MPT64, a protein secreted by Mycobacterium
tuberculosis complex, is highly specific for TB, making antibody to MPT64 a reagent specific for the diagnosis of TB.
Method: Antibody to MPT64 was obtained by a combination of genetic engineering and immunization by the
system evolution of ligands by exponential enrichment. A high-affinity aptamer of antibody to MPT64 was selected
from a random single-stranded DNA library, and a sandwich ELISA method based on this aptamer was developed.
This ELISA method was used to detect TB in 328 serum samples, 160 from patients with pulmonary TB (PTB) and
168 from non-tuberculous controls.
Results: The minimum limit of detection of the ELISA method was 2.5 mg/L, and its linear range varied from
10 mg/L to 800 mg/L. Its sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and area under the
curve, with 95 % confidence intervals, were 64.4 % (56.7 %–71.4 %), 99.4 % (96.7 %–99.9 %), 108.2 (15.3–765.9), 0.350
(0.291–0.442) and 0.819 (0.770–0.868), respectively. No significant difference in sensitivity was observed between
sputum smear positive (73/112, 65.2 %) and negative (30/48, 62.5 %) individuals.
Conclusions: This sandwich ELISA based on an MPT64 antibody aptamer may be useful for the serological
diagnosis of PTB, both in sputum smear positive and negative patients.
Keywords: MPT64 antibody, System evolution of ligands by exponential enrichment (SELEX), ssDNA, Aptamer,
Tuberculosis
Background
Being a contagious disease, tuberculosis (TB) poses a glo-
bal threat to human health. The World Health
Organization [1] reported that in 2010, there were 8.8 mil-
lion (range, 8.5–9.2 million) incident cases of TB, 1.1 mil-
lion (range, 0.9–1.2 million) deaths from TB among HIV-
negative individuals and 0.35 million (range, 0.32–0.39
million) deaths from HIV-associated TB. In China,
dramatic reductions in TB cases and deaths have been
achieved. Although the Stop TB Partnership target of
halving TB prevalence rates by 2015 compared with 1990
was unlikely to be achieved globally, this target had
already been reached in the Americas and was close to
being reached in the Western Pacific Region [1]. Two im-
portant factors have contributed to the resurgence and
morbidity of TB: (i) the emergence of multi-drug-resistant
and extensively drug-resistant strains of Mycobacterium
tuberculosis and (ii) the increasing incidence of HIV glo-
bally [2–6]. Most patients with TB have pulmonary TB
(PTB), and developing reliable laboratory tools is vital to
the diagnosis and treatment of PTB [7].
Antibody to MPT64 has been shown to bind MPT64
protein [8], a highly specific protein secreted by M.
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tuberculosis (MTB) complex, which includes M. tubercu-
losis, M. bovis and M. africanum [9–11]. Therefore, this
antibody may be useful in the detection of TB. We de-
scribe here the use of the systematic evolution of ligands
by exponential enrichment (SELEX) technique to de-
velop a sandwich ELISA method based on an MPT64
antibody aptamer for the diagnosis of PTB.
Materials and methods
Ethics Statement
All patients were treated in accordance with the Helsinki
Declaration on the participation of human subjects in
medical research. The study protocol was approved by
the Tongji University Ethics Committee (permit number:
K08-018), and informed consent was obtained from each
participant. Animal studies were approved by the Second
Military Medical University Animal Care and Ethics
Committee [approval ID: SYXK/2007-0003].
Preparation of antibody to MPT64
Based on the sequence of the H37Rv TB reference
strain encoding the MPT64 gene (accession number:
NC_000962), we designed forward (5'-CCCATATG
CGCATCAAGATCTTCAT-3') and reverse (5'-CCA
AGCTTGGCCAGCATCGAGTCG-3') primers, con-
taining Nde I and Hind III restriction sites, respect-
ively. PCR amplification with these primers was
performed using H37Rv nucleic acid as template.
Subsequently, the purified PCR product was inserted
into the T vector using ligase. After digestion with
restriction enzyme, pMD18-MPT64 was to pET21a
using T4 ligase and the pET21a-MPT64 expression
plasmid was used to transform BL21 (DE3) compe-
tent cells. Positive recombinant clones were identified
by DNA sequencing.
A recombinant clone was inoculated overnight into
the Luria Bertani medium at 37°C. The resultant bacteria
were lysed with ultrasound and the medium was centri-
fuged. The sediment was resuspended in 10 % Triton-X
100 buffer, and MPT64 protein was purified on a nickel-
agarose column. MPT64 protein was identified by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
[12] [Figure 1].
Rabbits were immunized with MPT64 protein by sub-
cutaneously injecting a suspension of 0.5 ml phosphate-
buffered saline (PBS] containing 0.5 g/L MPT64 protein
and 0.5 ml Freund's complete adjuvant into six sites on
the back of each rabbit. On days 14, 24, 34, and 44, each
rabbit was injected with the same dose of MPT64 pro-
tein and Freund's incomplete adjuvant. Rabbit serum
was collected, and MPT64 antibody was purified on a
CNBr-activated Sepharose 4B column, with the purified
antibody identified by western blotting [Figure 2]. The
details of the method have been described previously
[13]. Purified antibody was quantified by the Bradford
method [14].
Construction of a random single-stranded DNA (ssDNA)
library
Using the primers 5’-GGGAGCTCAGAATAAACGCT
CAA-3’ (forward) and 5’-Biotin-TTCGACATGAGGCCC
GGATC-3’ (reverse), a 78-mer ssDNA library was con-
structed with the sequences, 5’ -GGGAGCTCAGAA
TAAACGCTCAA-AN35-CGACATGAGGCCCGGATC-
3’, with the middle 35 sequences being random. The ran-
dom ssDNA library and primers were synthesized com-
mercially by Shanghai Sangon Company.
Selection of MPT64 antibody aptamer
The ssDNA library was optimized by PCR amplification
to obtain a double-stranded DNA (dsDNA) library. Fur-
thermore, the ssDNA library was constructed by using
asymmetric PCR. The amplified product was purified
with a phenol-chloroform-isoamyl alcohol mixture (vol-
ume ratios, 25:24:1)]. ELISA plates coated with bovine
serum were used to remove non-specific nucleotides
from the ssDNA library and the purified ssDNA library
added to microplates coated with antibody to MPT64.
The plates were washed six times with SELEX buffer.
SELEX eluate (20.0 mM Tris-HCl, 4.0 mM guanidinium
isothiocyanate, 1.0 mM 1,4-dithiothreitol; pH 8.3) was
added and allowed to incubate at 80°C for 10 min. The
ssDNA was extracted with a phenol-chloroform-ethanol
mixture. Using the extracted ssDNA as a template,
asymmetric PCR was performed. Then, the next round
of screening was performed. The parameters of the
SELEX assay are shown in Table 1.
After 12 rounds of aptamer selection, the absorbance
of the ssDNA reached its maximum value and a single
electrophoretic stripe was displayed. This indicated that
the purified ssDNA library with high affinity to the anti-
MPT64 antibody was saturated. The PCR products were
purified using the TIANgen Midi Purification Kit
(TIANgen Biotech [Beijing] Co., Ltd.) and subcloned
into a pMD 18-T vector with a TA cloning kit (TaKaRa,
Dalian, China). The resultant bacteria were used to
transform Escherichia coli DH5α strains, and individual
bacterial clones were selectively sequenced by a com-
mercial company (Sangon, Shanghai, China).
The affinity of the selected ssDNA aptamers was mea-
sured by ELISA. Polystyrene microplates were coated
overnight at 4°C with 10 μg/well of anti-MPT64 anti-
body in 100 μl 0.1 M NaHCO3 (pH 9.4), washed four
times with washing buffer (PBS containing 0.05 %
Tween 20, pH 7.4) and incubated for 1 hour at room
temperature with 200 μl of blocking buffer. The micro-
plates were washed once with washing buffer and
1.0 μg/well of biotin-labeled DNA aptamer in a binding
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buffer (SHCMK) containing 20.0 mM Hepes, pH 7.35,
1.0 mM CaCl2, 120 mM KCl and 1.0 mM MgCl2 was
added. The aptamers and MPT64 antibody were allowed
to react at 37°C for 40 min. The plates were washed six
times with washing buffer (SHCMK+0.05 % Tween 20)
and incubated at 37°C for 30 min with 100 μl/well of
streptavidin-horseradish peroxidase (Sigma, USA)
diluted 1:1000 in PBS. Finally, the plate was washed six
times with PBST and 100 μl of 1.0 mM tetramethylben-
zidine in citrate buffer (0.1 M, pH 4.25), with 2.0 mM
H2O2 added as substrate in a ratio of 1:20. The
enzymatic reaction was stopped 5 min later by the
addition of 50 μl 1.0 M H2SO4 and optical density (OD)
of 450 nm was measured spectrophotometrically.
Sandwich ELISA based on the anti-MPT64 antibody
aptamer
We assessed the secondary structures of the aptamers
using sequencing results and the DNAMAN version 4.0
(Lynnon Corporation, Quebec, Canada). The aptamer
with highest affinity to the anti-MPT64 antibody was
regarded as the capture and detection aptamer by
ELISA. Each microplate well was coated with 0.1 μg of
the capture aptamer, and the 5 ' end of the detection
aptamer was labeled with biotin. Based on the detection
of purified anti-MPT64 antibody at different dilution
ratios, the minimum limit of detection and the linear
range of this ELISA method were determined.
Serum samples, participant characteristics and validation
of the ELISA
We obtained 328 serum samples, 160 from patients
with definite PTB and 168 from non-tuberculous
controls including 78 healthy volunteers and 90 non-
tuberculous patients. All participants were confirmed
as being serologically HIV-negative. Of the 90 non-
tuberculous patients, 35 had pneumonia, 40 had lung
Figure 1 SDS-PAGE analysis of MPT64 protein obtained by genetic recombination. Lanes 1 and 3: markers; Lane 2: purified MPT64 protein
(24 kD); Line 4: purified polyclonal antibody to MPT64 (50 kD).
Figure 2 Western blot for detecting MPT64 purified
recombination protein. Line 1: control (non-induced recombinant
bacteria); Line 2: purified MPT64 recombination protein (24 kD).
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cancer, and 15 had lung abscesses and other condi-
tions. Lowenstein-Jensen (L-J) culture was performed
on all of these subjects to rule out TB.
The median ages of the PTB (31 years; range, 12–
73 years; IQR [interquartile range], 17–45 years) and
non-tuberculous controls (28 years; range, 14–69 years;
IQR, 18–42 years) did not differ significantly P> 0.05).
Patients were diagnosed with PTB by physicians based
on the criteria of the Chinese Anti-tuberculosis Asso-
ciation, mainly including continuous fever and cough
for more than 3 weeks, abnormal chest X-ray, weight
loss and the demonstration of TB in sputum by L-J
culture and standard biochemical identification tests.
Sputum smear examinations for PTB and non-
tuberculous patients were performed using the Ziehl-
Neelsen method at the same time as L-J culture
inoculation.
Statistical analysis
The sensitivity, specificity, positive likelihood ratio
(PLR), negative likelihood ratio (NLR) and area
under the curve (AUC), each with 95 % confidence
interval (CI), were calculated. All statistical analyses
were performed using Stata version 9 (Statacorp,
Texas, USA).
Results
Affinity, sequencing and secondary structure of ssDNA
aptamers
The OD values of ssDNA aptamers against MPT64 anti-
body (reflecting affinity) ranged from 0.55 to 1.62
[Table 2]. We elected MPT64-A1, which had a higher af-
finity (OD value: 1.62) than did the capture aptamer for
ELISA. The sequences of aptamer included forward fixed
sequences (5’- GGGAGCTCAGAATAAACGCTCAAA-
3’), random sequences (5’- AACGCTCAAGAGGCCCG
GATC-3’) and reverse fixed sequences (5’-TTCGAC
ATGAGGCCCGGATC-3’). The DNAMAN package pre-
dicted that the secondary structure of MPT64-A1 is a
stem-loop structure, similar to a large pocket [Figure 3].
Minimum detection limit and linear range of this ELISA
Based on the detection of the purified MPT64 antibody
at different dilution ratios, we found that the limit of de-
tection of this method was 2.5 mg/L and the linear range
varied from 10 mg/L to 800 mg/L [Figure 4].
Performance of the ELISA for serological diagnosis of PTB
In diagnosing PTB, this method had a sensitivity, specifi-
city, PLR, NLR, and AUC, with 95 % CI, of 64.4 %
(56.7 %–71.4 %), 99.4 % (96.7 %–99.9 %), 108.2 (15.3–
Table 2 Affinities of ssDNA aptamers to anti-MPT64 antibody
Name of aptamers OD value Name of aptamers OD value Name of aptamers OD value
MPT64-A1 1.62 MPT64-A5 0.93 MPT64-A9 1.24
MPT64-A2 0.82 MPT64-A6 0.55 MPT64-A10 1.12
MPT64-A3 0.78 MPT64-A7 0.90 MPT64-A11 1.10
MPT64-A4 0.96 MPT64-A8 1.33 MPT64-A12 1.06
Table 1 Parameters during each round of the SELEX assay
SELEX rounds Antibody (μg/well) ssDNA(μg/well) Reaction time in BSA-




1 1 0.5 15 60
2 0.5 0.5 20 60
3 0.25 0.5 20 60
4 0.25 0.1 30 45
5 0.1 0.1 30 45
6 0.25 0.1 30 45
7 0.1 0.1 45 30
8 0.1 0.05 45 30
9 0.05 0.05 45 30
10 0.05 0.025 60 20
11 0.025 0.025 60 20
12 0.025 0.01 60 15
Zhu et al. BMC Infectious Diseases 2012, 12:96 Page 4 of 8
http://www.biomedcentral.com/1471-2334/12/96
765.9), 0.35 (0.291–0.442), and 0.819 (0.770–0.868), re-
spectively [Table 3]. Its sensitivity was similar for sputum
smear positive (73/112, 65.2 %) and negative (30/48,
62.5 %) individuals [Table 4].
Discussion
MPT64 protein is one of the main filtrate proteins
secreted by MTB complex at an early stage. This protein
is encoded by the Rv1980c gene, contains 228 amino
acids and has a molecular mass of about 24,000 Da. It is
a specific protein, being secreted only by the MTB com-
plex [15–18]. In skin tests, this protein has a sensitivity
of 87.8 % and a specificity of 100 % for diagnosing active
TB [19,20]. Except for the MTB complex, bioinformatics
showed no epitopes similar to MPT64 protein, indicat-
ing its uniqueness. Furthermore, few BCG vaccines ex-
press MPT64 protein [17], suggesting that anti-MPT64
antibody may be specific for the diagnosis of TB. There-
fore, using a combination of immunization and genetic
engineering with SELEX, we developed a sandwich
ELISA method based on an anti-MPT64 antibody apta-
mer for the diagnosis of PTB.
SELEX [21,22] is a combinatorial chemistry technique
used in molecular biology to produce single-stranded
Figure 3 Secondary structure of the aptamer MPT64-A1 predicted by DNAMAN.
Figure 4 Linear range and minimum detection limit of the ELISA method.
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DNAs or RNAs that specifically bind ligands. SELEX can
be used to select high affinity aptamers against target
ligands and to obtain specific aptamers from an in vitro
pool of random aptamers. SELEX methods have improved
drastically in recent years, and several innovative SELEX
approaches have been developed, including counter-SELEX
, tissue-SELEX, cell SELEX (TECS-SELEX), fluorescent
bead SELEX (FluMag-SELEX), capillary electrophoresis
SELEX (CE-SELEX), neutral SELEX, and non-SELEX [23–
31]. SELEX was recently used to develop a aptamers against
counterpart target ligands, such as Campylobacter jejuni
[32]; C-reactive protein [33]; heterogeneous nuclear ribonu-
cleoproteins (hnRNPs) A1 [34]; hepatitis C virus envelope
glycoprotein E, botulinum neurotoxin [35]; the carboxyl
terminus of Kirsten rat sarcoma viral oncogene homolog
(K-RAS) protein [36], adenosine [37] and others. Some
aptamers against cancer-related proteins, such as platelet-
derived growth factor, vascular endothelial growth factor
(VEGF), human epidermal growth factor receptor 2, nu-
clear factor κB, tenascin-C and prostate-specific membrane
antigen [24,38–40], have also been selected. Moreover,
aptamers against whole cells, particularly cancer cells, have
been selected [38,41–46]. The aptamers selected by SELEX
were demonstrated to have potential clinical value [47–50].
For example, pegaptanib (Macugen), used to treat neovas-
cular age-related macular degeneration, and the anti-VEGF
aptamer pegaptanib used to treat human ocular vascular
disease, have received approval by the US Food and Drug
Administration [51,52]. In summary, SELEX has attracted
widespread attention and the selected aptamers have been
used in clinical diagnosis, treatment and drug development.
Functionally, an aptamer is similar to a protein antibody
complex obtained following immunization. Among the
advantages of aptamers over classical protein antibody
complexes are (1) higher specificity and affinity; (2) its
binding to a greater variety of target ligands, including
biological macromolecules, small molecule organic com-
pounds, inorganic ions, pathogenic microorganisms, and
cells; (3) increased convenience and lower cost; and (4)
greater stability, including storage at room temperature.
We have utilized the SELEX method to obtain apta-
mers against anti-MPT64 antibody in order to develop
an ELISA method for the diagnosis of TB. Following 12
rounds of screening, we observed a single electrophor-
etic strip, indicating that the purified ssDNA library with
a high affinity for anti-MPT64 antibody was saturated.
However, we observed differences in the affinities of
the selected aptamers. Its OD showed that MPT64-A1
had the highest affinity of all aptamers, whereas DNA
sequencing showed that absorbances for detecting affin-
ity were relatively constant. We found only small differ-
ences among the absorbance values for aptamers with
single base differences at the 5', whereas differences in
nucleotides at the stem-loop structure at the 3' end had
significant effects on affinity to anti-MPT64 antibody.
This suggested that the stem-loop structure may be the
site at which aptamers bind to the MPT64 antibody. The
secondary structure predicted by DNAMAN indicated
that MPT64-A1 could form a stem-loop structure like a
large pocket.
We found that the limit of detection of our ELISA
method was 2.5 mg/L, with a linear range varying from
10 mg/L to 800 mg/L. This suggested that this method was
sensitive and could have potential clinical value. ELISA had
a high specificity (99.4 %, 95 % CI: 96.7 %–99.9 %) and PLR
108.2 (15.3–765.9) and was appropriate for diagnostic pur-
poses. However, this method had a sensitivity of 64.4 %
(95 % CI: 56.7 %–71.4 %) and an NLR of 0.350 (95 % CI:








(%, 95 % CI)
Specificity








103 1 64.4 99.4 108.2 0.358 0.819
Negative
(n = 224)
57 167 (56.7–71.4) (96.7–99.9) (15.3–765.9) (0.291–0.442) (0.770–0.868)
PLR: positive likelihood ratio. NLR: negative likelihood ratio. CI: confidence interval. PTB: pulmonary tuberculosis. AUC: area under the curve.
Table 4 ELISA based on an anti-MPT64 antibody aptamer for serological diagnosis of pulmonary tuberculosis with
sputum smear positive and negative patients
Smear χ2 p
valuePositive (n = 112) Negative (n = 48)
ELISA Positive (n = 103) 73 30 0.105 0.746
Negative (n = 57) 39 18
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0.291–0.442), suggesting that this method was not suitable
for screening purpose. The AUC (0.819, 95 % CI: 0.770–
0.868) showed the reliability of this ELISA method. In
addition, the similar sensitivities observed in sputum smear
positive and negative patients suggested that this ELISA
method may be suitable for the serological diagnosis of spu-
tum smear negative individuals. Since sandwich ELISA is a
rapid, simple and very common test used by many labora-
tories and laboratory staff [53], it should prove feasible and
useful in resource-limited settings.
However, we did not include subsets of patients
infected with HIV/TB [54], indicating that the clinical
value of this ELISA method for a HIV-endemic popula-
tion remains unknown. Moreover, this study involved
only a few specific populations from hospital settings.
Therefore, further studies in different and more exten-
sive populations are necessary to evaluate the power of
this test for the diagnosis of TB.
Conclusions
Using a combination of genetic engineering with SELEX
and rabbit immunization, we developed a novel sand-
wich ELISA based on an anti-MPT64 antibody aptamer.
Clinical validation showed that this ELISA method was a
reliable test for the serological diagnosis of PTB and
could be used especially for diagnostic purposes. How-
ever, this ELISA method could also be suitable for sero-
logical diagnosis of sputum smear negative populations.
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